Press Releases

Press Releases (5)

CAMBRIDGE, Mass., October 4, 2017 – Semma Therapeutics, a biopharmaceutical company developing stem cell-derived islet (SC-islet) technology for type 1 diabetes (T1D), today announced it will present on its encapsulated stem cell-derived human islets in…
Read more
CAMBRIDGE, Mass., March 22, 2017 – Semma Therapeutics, a biopharmaceutical company developing Stem Cell-derived Islet therapy for type 1 diabetes (T1D), today announced it has received an investment from the JDRF T1D Fund, a venture…
Read more
CAMBRIDGE, Mass., November 7, 2016 – Semma Therapeutics, a biopharmaceutical company developing cellular therapies for the treatment of diabetes, announced today that Mark Fishman, M.D., has joined its Board of Directors as Chairman.
Read more
CAMBRIDGE, Mass., March 18, 2015 – Semma Therapeutics, a company developing a cell therapy for Type 1 diabetes, announced today that it has closed a $44 million Series A consisting of equity financing and strategic…
Read more
CAMBRIDGE, Mass., September 12 th , 2016 – Semma Therapeutics, a biopharmaceutical company developing cellular therapy for diabetes, announced today that it has accepted a $5 million grant from the California Institute of Regenerative Medicine…
Read more